- Global Pharma News & Resources

Biosimilars Market 2023: Ready to Record $143.6 Billion by 2031, Report

Biosimilars are drugs that are similar to biologic medicines that have already been approved by regulatory agencies. They are designed to be less expensive alternatives to the original biologic drugs, and they can provide similar clinical benefits.

The biosimilars market is a growing industry that includes companies that develop, manufacture, and sell these drugs. The market is driven by the need for more affordable options for treating a range of diseases, including cancer, autoimmune disorders, and other chronic conditions.

In simple terms, the biosimilars market is a way for patients to access effective treatments at a lower cost than the original biologic drugs. It is a competitive industry that is constantly evolving, with new drugs being developed and approved regularly.

Allied Market Research analyzes that the global biosimilars industry was estimated at $15.9 billion in 2021, and is anticipated to hit $143.6 billion by 2031, registering a CAGR of 24.7% from 2022 to 2031.

Download the Exclusive Sample Report (Including Graphs, Charts & Table & Figures) @

These segments can be broadly categorized as follows:

  • Pharmaceutical Companies: These are companies that develop and manufacture biosimilars. They invest in research and development to create these drugs and bring them to market.
  • Contract Research Organizations (CROs): These are companies that offer research and development services to pharmaceutical companies. They can help with various aspects of biosimilar development, such as clinical trials and regulatory compliance.
  • Regulatory Agencies: These are government agencies that oversee the approval and regulation of biosimilars. In the United States, the Food and Drug Administration (FDA) is the regulatory agency responsible for this.
  • Distributors and Wholesalers: These are companies that help to distribute biosimilars to hospitals, pharmacies, and other healthcare providers.
  • Healthcare Providers: These are doctors, nurses, and other healthcare professionals who prescribe and administer biosimilars to patients.
  • Patients: These are the end-users of biosimilars. They are the individuals who use these drugs to treat various medical conditions.

Increase in incidences of diabetes and autoimmune diseases drives the growth of the global biosimilars market. Moreover, favorable government policies and new product launches in the biosimilars industry have supplemented the growth yet more. Moreover, several growth prospects in the developed as well as developing economies have been beneficial for the key players in the industry.

The global biosimilars market is a dynamic industry that is influenced by several factors, including:

  • Patent Expirations: The biosimilars market is driven by the expiration of patents for original biologic drugs. As these patents expire, biosimilar manufacturers can develop and market their own versions of these drugs, leading to increased competition and lower prices.
  • Increasing Demand for Cost-Effective Treatment Options: As healthcare costs continue to rise, there is a growing demand for more cost-effective treatment options. Biosimilars offer a lower-cost alternative to original biologic drugs, which can help to reduce healthcare spending.
  • Regulatory Environment: The regulatory environment plays a significant role in the biosimilars market. Regulatory agencies, such as the FDA, have established guidelines for the development and approval of biosimilars, which can impact the speed and cost of bringing these drugs to market.
  • Technological Advances: Advances in biotechnology and manufacturing processes have made it easier and more cost-effective to develop and produce biosimilars. This has led to an increase in the number of companies entering the market and a greater availability of these drugs.
  • Competitive Landscape: The biosimilars market is highly competitive, with many companies vying for market share. This has led to price competition and a focus on developing drugs with improved efficacy and safety profiles.

Overall, the biosimilars market is expected to continue to grow in the coming years, driven by factors such as increasing demand for cost-effective treatment options, patent expirations, and advances in biotechnology and manufacturing processes.

Some of the key developments in the biosimilars industry include:
  • Regulatory Pathways: Regulatory agencies such as the FDA and the European Medicines Agency (EMA) have established regulatory pathways for the approval of biosimilars, providing clear guidance for manufacturers on the development and testing of these drugs.
  • Improved Manufacturing Processes: Advances in biotechnology and manufacturing processes have led to the development of more efficient and cost-effective methods for producing biosimilars, making these drugs more accessible to patients.
  • Increased Competition: As more companies enter the biosimilars market, competition has increased, leading to lower prices and greater access to these drugs.
  • Expanded Use: Biosimilars are being developed for a growing number of therapeutic areas, including oncology, immunology, and endocrinology, among others. This is expanding the range of treatment options available to patients.
  • Global Expansion: The biosimilars market is expanding globally, with increasing development and uptake in markets such as Asia and Latin America.

๐๐ซ๐จ๐œ๐ฎ๐ซ๐ž ๐‚๐จ๐ฆ๐ฉ๐ฅ๐ž๐ญ๐ž ๐‘๐ž๐ฉ๐จ๐ซ๐ญ (๐Ÿ๐Ÿ๐ŸŽ ๐๐š๐ ๐ž๐ฌ ๐๐ƒ๐… ๐ฐ๐ข๐ญ๐ก ๐ˆ๐ง๐ฌ๐ข๐ ๐ก๐ญ๐ฌ, ๐‚๐ก๐š๐ซ๐ญ๐ฌ, ๐“๐š๐›๐ฅ๐ž๐ฌ, ๐š๐ง๐ ๐…๐ข๐ ๐ฎ๐ซ๐ž๐ฌ) @

The top companies in the biosimilars market (based on revenue and market share) are:

  1. Pfizer
  2. Sandoz (a subsidiary of Novartis)
  3. Celltrion
  4. Biocon
  5. Amgen
  6. Samsung Bioepis
  7. Teva Pharmaceutical Industries
  8. Boehringer Ingelheim
  9. Mylan
  10. Fresenius Kabi

The biosimilars market faces several challenges, including:

  • Regulatory Hurdles: The regulatory process for biosimilars can be complex and lengthy, which can delay market entry and increase development costs. Additionally, there can be challenges in demonstrating biosimilarity and safety to regulatory agencies.
  • Intellectual Property Issues: The biosimilars market is heavily influenced by patents, and there can be legal challenges surrounding the development and marketing of biosimilars due to patent infringement issues.
  • Manufacturing Complexities: Biosimilars are complex drugs that require specialized manufacturing processes, which can be difficult and expensive to scale up to commercial levels.
  • Competition from Biologics: Original biologic drugs may continue to dominate the market due to their established safety and efficacy profiles, which can make it difficult for biosimilars to gain market share.

Browse a Detailed Summary of Research Report @

The biosimilars market offers several opportunities, including:

  • Increased Patient Access: Biosimilars can provide a more cost-effective alternative to original biologic drugs, making these treatments more accessible to patients who might otherwise be unable to afford them.
  • Growing Demand for Biologic Drugs: As the population ages and chronic diseases become more prevalent, there is an increasing demand for biologic drugs. Biosimilars offer a lower-cost alternative to original biologics, providing an opportunity to meet this growing demand.
  • Expanding Global Markets: The biosimilars market is expanding globally, with increasing development and uptake in markets such as Asia and Latin America. This presents an opportunity for companies to expand their business and access new markets.
  • Patent Expirations: As patents for original biologics expire, there is an opportunity for biosimilar manufacturers to develop and market their own versions of these drugs, providing a new source of revenue for these companies.

๐‘๐ž๐ช๐ฎ๐ž๐ฌ๐ญ ๐‚๐ฎ๐ฌ๐ญ๐จ๐ฆ๐ข๐ณ๐š๐ญ๐ข๐จ๐ง:

Global Biosimilars Market Scope

The global biosimilars market includes biologic drugs that are similar to existing biologic drugs, but which are developed and marketed by different manufacturers. The scope of the biosimilars market is broad and encompasses a wide range of therapeutic areas, including oncology, immunology, endocrinology, and more. The market includes biosimilars that are developed and marketed in various forms, including injectable, subcutaneous, and intravenous formulations.

The global biosimilars market is driven by several factors, including the growing demand for biologic drugs, increasing healthcare costs, and the need to improve patient access to affordable treatments. The market is also influenced by factors such as patent expirations, regulatory developments, and advances in biotechnology.

๐“๐ซ๐ž๐ง๐๐ข๐ง๐  ๐‘๐ž๐ฉ๐จ๐ซ๐ญ๐ฌ ๐ข๐ง ๐‡๐ž๐š๐ฅ๐ญ๐ก๐œ๐š๐ซ๐ž ๐ˆ๐ง๐๐ฎ๐ฌ๐ญ๐ซ๐ฒ (๐๐จ๐จ๐ค ๐๐จ๐ฐ ๐ฐ๐ข๐ญ๐ก ๐Ÿ๐ŸŽ% ๐ƒ๐ข๐ฌ๐œ๐จ๐ฎ๐ง๐ญ):

Body Composition Analyzers Market

Ophthalmic Devices Market

Contraceptive Drugs Market

๐€๐›๐จ๐ฎ๐ญ ๐€๐ฅ๐ฅ๐ข๐ž๐ ๐Œ๐š๐ซ๐ค๐ž๐ญ ๐‘๐ž๐ฌ๐ž๐š๐ซ๐œ๐ก:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of โ€œMarket Research Reportsโ€ and โ€œBusiness Intelligence Solutions.โ€ AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI.

Editor Details

  • Company:
    • The Wire Times
Last Updated: 25-Apr-2023